The role of lymphoid tissue as a potential source of HIV-1 rebound following interruption of antiretroviral therapy is uncertain. To address this issue, we compared the latent viruses obtained from CD4 + T cells in peripheral blood and lymph nodes to viruses emerging during treatment interruption. Latent viruses were characterized by sequencing near full-length (NFL) proviral DNA, and env from viral outgrowth cultures (VOAs). 5 HIV-1 infected individuals on antiretroviral therapy (ART) were studied, 4 of whom participated in a clinical trial that included an analytical treatment interruption. Intact or replication competent clonal sequences from blood and lymph node overlapped. In contrast, there was no overlap between 205 latent reservoir and 125 rebound sequences in the 4 individuals who underwent treatment interruption. However, rebound viruses could be accounted for by recombination. The data suggests that CD4 + T cells carrying latent viruses circulate between blood and lymphoid tissues in individuals on ART and support the idea that recombination may play a role in the emergence of rebound viremia.
Introduction
ART is an effective treatment for HIV-1 infection. However, HIV-1 persists as proviral DNA in CD4 + T cells and produces a latent reservoir that demonstrates remarkable stability (1-3). Upon ART interruption, nearly all individuals experience viral rebound within 1-6 weeks (4-6). However, most integrated proviruses are defective (7, 8) , and only a small percentage can replicate and produce the infectious virions that mediate rebound viremia when ART is interrupted. Latent viruses can be recovered from the reservoir by viral outgrowth assays (VOA) and by polymerase chain reaction amplification of integrated proviruses (9, 10) . Using these methods latent viruses have been recovered from lymph nodes, gut-associated lymphoid tissue (GALT), spleen, CNS, liver, lungs, kidney, adipose tissue and genital tract (11) (12) (13) (14) (15) (16) (17) .
In 4 recent studies, comparison of circulating latent viruses and rebound viruses showed a very limited number of overlapping sequences (10, (18) (19) (20) . One potential explanation for this observation is that latent viruses found in CD4 + T cells in lymphoid and other tissues differ from those in circulation, and that these sequestered cells are responsible for the rebound viremia. To examine the relationship between latent viruses in circulation and in lymph node, we studied 5 individuals who had concurrent blood draws and lymph node biopsies. Rebound plasma was available for 4 of these individuals who were enrolled in a clinical trial that included an analytical treatment interruption after 24 weeks of therapy with a TLR9 agonist.
Results

Samples and study participants
To investigate the intact proviral reservoir, we obtained mononuclear cells from lymph nodes (LNMC) and peripheral blood (PBMC) from 4 ART treated HIV-1 infected individuals (extended data table 1a), who had been virally suppressed for a median of 8.3 years (range 1. 8-13.4 ). All 4 participated in an interventional trial in which a TLR9 agonist was co-administered with ART for 24 weeks (figure 1a) (21) . PBMCs and LNMCs were collected in the last 2 weeks of the 24 week period. Subsequently ART was interrupted until viral rebound. Plasma was collected before ART re-initiation. Time from ART withdrawal to viral rebound was between 9-15 days (figure 2a) which is not significantly different from a non-interventional ATI control cohort of 52 participants (ACTG cohort) (22-24) (figure 2b, P = 0.5, Log-rank test). In addition, we obtained PBMCs and LNMC from an HIV-1 infected individual (ID LFSO), who had been on ART for 1.3 years without additional interventions or treatment interruption (extended data table 1b). To obtain full-length env sequences from viruses that were replication competent and/or genetically intact, CD4 + T cells from blood and lymph node were assayed by VOA, and near full-length (NFL) PCR (10) (extended data table 2).
Intact and defective latent viruses from blood and lymph node CD4 + T cells overlap
We obtained 205 latent virus sequences: 93 and 79 intact NFL sequences from blood and lymph node, respectively, and 33 from VOA from blood (extended data table 2). 44% of all sequences belonged to expanded clones, 98% of which overlapped between blood and lymph node (i.e. identical sequences). There were no statistical differences between the frequency of clonal sequences in blood compared to lymph node (two sided Fisher's exact test, p-values in extended data table 3a). Clones were absent in participants ID 114 and ID 120 where sample availability was more limited and latent viruses were diverse.
To determine whether defective viruses were also similar between blood and lymph node, we combined intact and defective env sequences from all NFL and VOAs (327 sequences) (extended data figure 1). Overall 43% of all env sequences belonged to expanded clones (143 sequences), and 89% of the clones overlapped between blood and lymph node (two sided Fisher's exact test, pvalues in extended data table 3b). We conclude that CD4 + T cells in peripheral blood and lymph node contain overlapping sets of proviruses.
The frequency of intact viruses in blood and lymph node
To further examine the relative proviral nucleic acid content in peripheral blood and lymph node, we compared the frequency of: 1) GAG+ cells; 2) full-length genomes; and 3) intact NFL proviruses (figure 1c). The frequency of GAG+, full-length genomes and intact NFL per 10 6 CD4 + T cells was not statistically different between peripheral blood and lymph node (figure 1c). Thus, in our cohort the frequency of intact and defective HIV-1 proviruses in CD4 + T cells is similar in peripheral blood and lymph node.
Relationship between plasma rebound viruses and reservoir viruses
125 full-length env sequences were obtained by SGA from rebound plasma, none of which overlapped with any of the latent reservoir sequences ( figure 3 ). Nevertheless, phylogenetic analysis revealed that plasma rebound viruses were related to latent viruses in peripheral blood and lymph node from the same individual (figure 4a and 4b). Thus, the latent viruses obtained from peripheral blood and lymph node are related to, but do not appear to be the direct origin of rebound virus in these individuals.
To determine whether mutations accumulating during rebound can account for the divergence between the latent reservoir and rebound viruses we used a stochastic mutation simulation model (20, 25, 26) (extended data figure 2). We found no instance in which rebound sequences could be accounted for by mutation. To determine whether recombination between latent blood and lymph node viruses could account for the rebound viruses we analyzed intact NFL, and VOA env sequences using the 3SEQ recombination algorithm (http://mol.ax/software/3seq/). Rebound viruses in all 4 individuals showed evidence of recombination (figure 4a, b, i.e. rejection of the null hypothesis of clonal evolution; p-values in extended data table 4 and 5). By including the possibility of mutation and recombination, we were able to account for 53% of the rebound sequences.
Discussion
HIV-1 proviruses are present in lymphoid cells in all tissues analyzed to date (11) (12) (13) (14) (15) (16) (17) . However, the relationship between viruses found in different sites and their contribution to persistence is not well defined. Our data suggest that the latent viruses found in circulation overlap with those found in lymph nodes and that the most prevalent viruses in these compartments are not typically found among rebound viruses during treatment interruption.
It has been suggested that lymph nodes serve as a sanctuary site for latent HIV-1 (27, 28) . However, we found the same overall frequency of HIV-1 proviruses in blood and lymph node CD4 + T cells.
Moreover, the two compartments contained similar numbers of replication competent viruses, and shared clones of latent viruses. Thus, expanded CD4 + T cell clones bearing latent viruses circulate between these two compartments. Finally, rebound viruses did not overlap with either blood or lymph node, but instead appeared to represent recombinants.
Our findings are consistent with a number of previous observations indicating that there are similar amounts of HIV-1 DNA in CD4 + T cells in blood and in tissues (29, 30) . However, our work is limited by the numbers of individuals and CD4 + T cells analyzed and therefore we cannot rule out the possibility that a subset of lymph node cells, such as CD4 + T FH cells, are enriched in or harbor a specific group of latent viruses (31) .
Three other studies have also shown little or no overlap between circulating latent viruses and rebound viruses (10, 19, 20) . Including the data reported here, there are only 3 overlapping sequences among 1816 independently derived latent reservoir viruses and 642 rebound viruses.
Instead, the latent and rebound compartments appear to be related by recombination.
There are a number of potential explanations for the lack of concordance between latent and rebound viruses. One possibility is that latent reservoir sampling has been inadequate. For example, the active reservoir responsible for rebound might be found primarily in a tissue that has not been assayed, such as the gut. A second non-exclusive possibility is that the majority of the latent viruses in blood and lymph node fail to emerge in vivo because they are in some way unfit to do so. For example, the majority of latent viruses assayed could be susceptible to immune pressure resulting in selection of a subset of rebound viruses which can escape anti-viral immunity in vivo possibly by recombination (32, 33) .
In conclusion, the data reported indicated that the majority the latent clonal viruses found in blood are also found in the lymph nodes and add to the growing body of literature suggesting that rebound viruses are either not present in or are rare components of the latent reservoir found in circulation. (22)) were used to compare to viral rebound data from the 4 participants in this study.
Materials and Methods
Study Design and participants
The studies were carried out as an ATI without any further interventions and included 52 participants. Inclusion criteria for the ACTG cohort were: age 18-65, on cART>12 months, plasma HIV-1 RNA<50 c/mL>12 months before ATI initiation, CD4 + T cell count at time of ATI initiation>500 cells/µl, nadir CD4 + T cell count>200 cells/µl. Viral load was measured weekly until viral rebound occurred.
Viral outgrowth assay (VOA)
The VOA was performed using PBMCs from peripheral blood (PB) as previously described with some modifications (34) . Briefly, PBMCs were isolated by density centrifugation on Ficoll (Thermo Scientific). CD4 + T cells were isolated from the cryopreserved PBMCs through negative selection with magnetic beads (Miltenyi). Purified CD4 + T cells (0. MOLT4-CCR5 cells were added to each well as target cells. At day 5, 100 µL of medium was replaced with fresh media. At day 14, the supernatant of each well was tested for p24 production using ELISA as previously described (35) .
VOA Sequence Amplification
Extraction of RNA and generation of cDNA and amplification of full-length env was performed as previously described (see extended data table 6 for a list of primers) (34, 36) . The 1% 96-well E-Gels (Invitrogen) were used to visualize amplified env PCR products and select the bands with the expected HIV-1 envelope size. Selected PCR products were subjected to library preparation using Illumina Nextera DNA Sample Preparation Kit (Illumina) as previously described (34) . Briefly, DNA was diluted in nuclease-free water to 10-20 ng per well and subjected to tagmentation. The Illumina Nextera Index Kit was then used to ligate tagmented DNA to barcoded sequencing adapters. Subsequently AmPure Beads XP (Agencourt) were used to purify DNA. Each library consisted of 96 different samples, which were subjected to paired-end sequencing using Illumina MiSeq Nano 300 (Illumina) cycle kits at a final concentration of 12 pM.
Single-genome Amplification of Plasma Rebound Virus
Single-genome amplification (SGA) and sequencing of HIV-1 env genes was performed as previously described (37) (38) (39) .
Near Full-length Genome Amplification
CD4 + T cells were isolated from cryopreserved PBMCs and lymph node mononuclear cells (LNMC) using magnetic beads (Miltenyi). For genomic DNA extraction, we used Gentra Puregene Cell Kit (Qiagen), according to the manufacturer's instructions. Near full-length sequencing (NFL) was done by an initial limiting-dilution semi-nested PCR amplifying the gag gene using the primers 3GagIN, 5GAGIN, 3GAGININ. If these primers failed, we used the primers GAGB5out, GAGB3out, GAGB5in, GAGB3in as previously described (8, 9) (extended data table 6). Gag PCR products were visualized using 1% 96-well E-Gels (Invitrogen). Dilutions with < 30% positive of the PCR wells were selected for further analysis. According to Poisson statistics, this dilution has over 90% probability of containing one HIV-1 DNA molecule in each PCR reaction. The NFL HIV-1 genome was amplified as a nested PCR with primers and cycling conditions as previously described (8, 9, 36) . Briefly, the outer 9,064 bp PCR was performed using the primers BLOuterF and BLOuterR (extended data table 6) and High Fidelity Platinum Taq Polymerase (Invitrogen).
For the nested PCR, 0.75 µl was transferred and the env gene amplified using the primers envB5out and envB3out. Wells containing an intact env gene were selected using 1% 96-well E-Gels (Invitrogen) and the corresponding outer PCR products were collected for further analyzes. NFL outer PCR products were subjected to a nested PCR to generate four segments A, B, C, D comprising overlapping parts of the genome. The PCR products were visualized on a 0.8% agarose gel to determine amplicon size. PCR products with the accepted size (A: 4,449 bp; B: 5,793 bp; C: 6,385 bp; D: 4,778 bp) were combined as either A+C, A+D, B+C or B+D and subsequently subjected to library preparation and sequencing using Illumina MiSeq Nano 300 (Illumina) cycle kits at a final concentration of 12 pM, as described above. Assembly and analysis of HIV-1 genome sequencing was performed as previously described (10) .
Identification of intact proviruses and construction of phylogenetic trees
To identify intact NFL sequences, we aligned assembled sequences to HXB2. Hereby we could Maximum likelihood phylogenetic trees were constructed as previously described (10) . To assess for cross-contamination of samples, we also generated a neighbor-joining (NJ) tree, which included all sequences obtained for the entire analyses and hereby confirmed that all sequences clustered correctly (extended data figure 4 ).
Data availability
Sequence data generated in this study have been deposited in GenBank. Maximum likelihood phylogenetic trees showing all sequence names are in the supplementary material (extended data figure 5 )
Recombination analysis of env sequences
Multiple alignment of nucleotide sequences and the recombination analysis was performed as previously described (10, 20) . Briefly, env sequences from NFL, VOA and SGA rebound sequences were analyzed for occurrence of recombination by the 3SEQ recombination algorithm (http://mol.ax/software/3seq/). Sequences with statistical evidence of recombination (i.e. rejection of the null hypothesis of clonal evolution) are represented in a circos plot (http://circos.ca/).
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